

Classification: Biological Sciences, Population Biology

A personalized antibody score for predicting individual COVID-19 vaccine-elicited antibody levels from basic demographic and health information

Authors:

Naotoshi Nakamura^{1,†}, Hyeongki Park^{1,†}, Kwang Su Kim^{1,2,4,†}, Yoshitaka Sato³, Yong Dam Jeong^{1,4}, Shoya Iwanami¹, Yasuhisa Fujita¹, Tianchen Zhao⁵, Yuta Tani⁶, Yoshitaka Nishikawa⁷, Chika Yamamoto⁵, Yurie Kobashi^{5,7}, Takeshi Kawamura^{8,9}, Akira Sugiyama⁸, Aya Nakayama⁸, Yudai Kaneko^{9,10}, Kazuyuki Aihara¹¹, Shingo Iwami^{1,12,13,14,15,16*} and Masaharu Tsubokura^{5,7,17,*}

Affiliations:

¹interdisciplinary Biology Laboratory (iBLab), Division of Natural Science, Graduate School of Science, Nagoya University, Nagoya, Japan. ²Department of Science System Simulation, Pukyong National University, Busan, South Korea. ³Department of Virology, Nagoya University Graduate School of Medicine, Nagoya, Japan. ⁴Department of Mathematics, Pusan National University, Busan, South Korea. ⁵Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Japan. ⁶Medical Governance Research Institute, Tokyo, Japan. ⁷Department of General Internal Medicine, Hirata Central Hospital, Fukushima, Japan. ⁸Proteomics Laboratory, Isotope Science Center, The University of Tokyo, Tokyo, Japan. ⁹Laboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan. ¹⁰Medical & Biological Laboratories Co., Ltd., Tokyo, Japan. ¹¹International Research Center for Neurointelligence, The University of Tokyo Institutes for Advanced Study, The University of Tokyo, Tokyo, Japan. ¹²Institute of Mathematics for Industry, Kyushu University, Fukuoka, Japan. ¹³Institute for the Advanced Study of Human Biology (ASHBi), Kyoto University, Kyoto, Japan. ¹⁴Interdisciplinary Theoretical and Mathematical Sciences Program (iTHEMS), RIKEN, Saitama, Japan. ¹⁵NEXT-Ganken

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Program, Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan.

¹⁶Science Groove Inc., Fukuoka, Japan. ¹⁷Minamisoma Municipal General Hospital, Fukushima, Japan.

†These authors contributed equally to this study.

*To whom correspondence may be addressed.

Email: iwami.iblab@bio.nagoya-u.ac.jp (S.I.) and tsubo-m@fmu.ac.jp (M.T.)

1 **Abstract (248/250)**

2 Antibody titers wane after two-dose COVID-19 vaccinations, but individual variation in
3 vaccine-elicited antibody dynamics remains to be explored. Here, we created a personalized
4 antibody score that enables individuals to infer their antibody status by use of a simple calculation.
5 We recently developed a mathematical model of B cell differentiation to accurately interpolate the
6 longitudinal data from a community-based cohort in Fukushima, Japan, which consists of 2,159
7 individuals who underwent serum sampling two or three times after a two-dose vaccination with
8 either BNT162b2 or mRNA-1273. Using the individually reconstructed time course of the vaccine-
9 elicited antibody response, we first elucidated individual background factors that contributed to
10 the main features of antibody dynamics, i.e., the peak, the duration, and the area under the curve.
11 We found that increasing age was a negative factor and a longer interval between the two doses
12 was a positive factor for individual antibody level. We also found that the presence of underlying
13 disease and the use of medication affected antibody levels negatively, whereas the presence of
14 adverse reactions upon vaccination affected antibody levels positively. We then applied to these
15 factors a recently proposed computational method to optimally fit clinical scores, which resulted
16 in an integer-based score that can be used to evaluate the antibody status of individuals from
17 their basic demographic and health information. This score can be easily calculated by individuals
18 themselves or by medical practitioners. There is a potential usefulness of this score for identifying
19 vulnerable populations and encouraging them to get booster vaccinations.

20 **Significance statement (117/120)**

21 Different individuals show different antibody titers even after the same COVID-19
22 vaccinations, making some individuals more prone to breakthrough infections than others. Such
23 variability remains to be clarified. Here we used mathematical modeling to reconstruct individual
24 post-vaccination antibody dynamics from a cohort of 2,159 individuals in Fukushima, Japan.
25 Machine learning identified several positive and negative factors affecting individual antibody
26 titers. Positive factors included adverse reactions after vaccinations and a longer interval between
27 two vaccinations. Negative factors included age, underlying medical conditions, and medications.
28 We combined these factors and developed an “antibody score” to estimate individual antibody
29 dynamics from basic demographic and health information. This score can help to guide individual
30 decision-making about taking further precautions against COVID-19.

31

32 **Keywords:**

33 COVID-19, Vaccine-elicited antibody response, Feature engineering, Mathematical model,
34 Feature importance

35

36 \body

37 **Text**

38 The ongoing COVID-19 pandemic has caused more than 500 million cases and 6 million
39 confirmed deaths worldwide. The current COVID-19 vaccines, which became available in late
40 2020 to early 2021, have helped vaccine recipients acquire immunity against SARS-CoV-2 and
41 reduce their likelihood of infection and hospitalization (1, 2).


42 In the case of two-dose mRNA-based vaccines such as BNT162b2 and mRNA-1273,
43 antibody titers, on average, reach a peak around two weeks after the second vaccination and
44 decline thereafter. However, explanation of the individual variability in vaccine-elicited antibody
45 dynamics has remained elusive. Past studies addressing dynamics focused on the average of a
46 group of individuals (i.e., population-level dynamics) having specific demographic characteristics
47 such as age or sex (3-8) and thus have not led to personalized advice for individuals. Some
48 studies included only health care workers and did not cover the whole spectrum of the general
49 population, especially older adults and those with underlying medical conditions (4, 9-12). Most
50 of the other studies targeted at the general population lumped antibody measurements together
51 with different elapsed times since vaccination (12-17), making precise determination and
52 comparison of individual dynamics difficult.

53 Here, we used a mathematical model (developed in (18)) to describe the process of
54 differentiation from naïve B cells to plasma cells to accurately reconstruct individual vaccine-
55 elicited antibody dynamics in the Fukushima vaccination cohort (a community-based cohort in
56 Fukushima, Japan). The model parameters describe highly variable individual-level antibody
57 responses, allowing us to partially predict variation in vaccine response on the basis of personal
58 information including age, adverse reactions, comorbidities, and medication use. Furthermore,
59 we devised a useful personalized antibody score that allows individuals to predict their antibody
60 status from their personal information. The score can be used by medical practitioners to
61 encourage individuals with low predicted antibody levels to get booster vaccinations.

62 Results

63 Deriving measures of peak, duration, and area under the curve of vaccine-elicited antibody 64 dynamics

65 We fully reconstructed the dynamics of IgG(S) titers after the first vaccination for 2,159
66 individuals in the Fukushima vaccination cohort in **Supplementary Fig 1C** (see **Methods** in
67 detail) and extracted the “features” described in **Fig 1A** for each individual: the peak, duration,
68 and area under the curve (AUC) of the reconstructed antibody dynamics. To quantify these
69 features, we here assumed $A_{TH} = 100$ and determined t_s and t_e corresponding to the time for
70 the antibody titer to be greater than and smaller than A_{TH} , respectively. Therefore, the duration
71 and AUC of the antibody titer are formulated by $t_e - t_s$ and $\int_{t_s}^{t_e} A(s) ds$, respectively. In addition,
72 defining t_p to be the time for the antibody titer to reach its peak, the peak titer is $A(t_p)$. In **Fig**
73 **1B**, we summarized distributions of the AUC, duration, and peak for 2,159 participants. We then
74 compared these features among the participants. We used the logarithm (\log_{10}) of the peak and
75 of the AUC because these measures had a long-tailed distribution spanning at least two orders
76 of magnitude (**Supplementary Fig 2A**). The Pearson correlation matrix (**Fig 1C**) showed that the
77 AUC was highly correlated with the duration and the peak, meaning that the three features are
78 similar. Note that a similar trend was obtained under a different A_{TH} (data not shown). These
79 features allowed us to quantitatively compare vaccine-elicited antibody dynamics among the
80 participants (see next section).



81
82
83
84
85
86
87
88
89
90
91
92


Figure 1 | Quantifying vaccine-elicited antibody dynamics: **(A)** Vaccine-elicited antibody response after the first vaccination (i.e., $t = 0$) is described with the following “features”: the peak ($A(t_p)$), duration ($t_e - t_s$), and AUC ($\int_{t_s}^{t_e} A(s) ds$) of the antibody titers. The vertical and horizontal dashed lines correspond to the date of the second vaccination and the arbitrary threshold (A_{TH}) for calculating the duration and AUC, respectively. **(B)** Distributions of the extracted features from the reconstructed antibody dynamics (i.e., the peak, duration, and AUC) for 2,407 participants are plotted. The dataset for each distribution was normalized by the value corresponding to the 95th percentile of data values, and data whose values were larger than this value were removed to improve the visibility of the figure. **(C)** Heatmap plot showing Pearson correlation matrix describing three features (\log_{10} of peak, \log_{10} of AUC, duration) of antibody dynamics.

93 **Characterizing vaccine-elicited antibody dynamics**

94 To see how individual background factors contributed to the three features, we trained a
95 random forest regressor to predict the features from basic demographic information for the
96 participants, including underlying medical conditions, adverse reactions to vaccinations, and
97 medications, as described in **Supplementary Table 1**. The out-of-bag (OOB) R squared values
98 obtained were 15.9%, 27.9%, and 23.7% for the peak, AUC, and duration, respectively,
99 suggesting that the features can be partially explained by the background information available.
100 We visualized significant factors as a Chord diagram, in which the size of the arcs connecting
101 individual factors to each of the three features indicates their importance in predicting the feature
102 **(Fig 2A)**.

103 We used partial dependence plots to look into the dependence of these features on the
104 continuous variables, i.e., age and the interval between the two doses **(Fig 2B)**. All the features
105 decreased as age increased. Two features, the AUC and the peak, increased as the interval
106 increased. By contrast, the duration was smallest at the interval of 21 days and increased as the
107 interval became longer than that. However, we had only 13 participants with an interval of fewer
108 than 20 days and the difference between their duration and the duration of others was not
109 statistically significant ($p = 0.61$). We next looked at the dependence of the features on categorical
110 variables: we found that the presence of underlying diseases (collagen diseases and rheumatism)
111 and medication use (antihistamines, immunosuppressants, and steroids) affected the features
112 negatively, while the presence of adverse reactions affected the features positively. The result of
113 a similar analysis on the model parameters H_2 and m is shown in **Supplementary Fig 2B**.

114



115

116 **Figure 2 | Characterizing and scoring vaccine-elicited antibody dynamics: (A)** Chord
 117 diagram representing the most predictive factors of three “features” of antibody titers (i.e., peak,
 118 duration, and AUC) is shown. The size of the arc from a group to a feature is proportional to its
 119 importance as measured by Mean Decrease in Accuracy. Features with $p < 0.05$ are displayed.
 120 **(B)** Partial dependence plots showing the dependence of the three features on age or the interval
 121 between two vaccinations are shown. **(C)** Metric for calculating the “top AUC score,” i.e., a score
 122 to identify individuals with AUC in the top third of the population. **(D)** Left: Distribution of the top
 123 AUC scores in the test dataset: 19, 78, 92, 104, and 91 individuals had scores of -2 or less, -1, 0,
 124 1, or 2 or more, respectively. Those in the top third of the test dataset are shown in yellow, and
 125 those not in the top third are shown in orange. The ratio of individuals with AUC in the top third of
 126 the test dataset increased as the top AUC score increased. Right: the average AUC tended to
 127 increase as the top AUC score increased.

128 Deriving a personalized antibody score

129 Combining the above demographic and health information, we devised a simple score
130 that enables individuals to roughly estimate their antibody status. We chose the AUC of the
131 antibody dynamics as a representative feature of individual antibody status, because the other
132 features (the peak and the duration) are highly correlated with and similar to the AUC (**Fig 1C**).
133 Recently, a systematic approach to fit optimized scores with mixed-integer nonlinear
134 programming was proposed (19). We applied this method to construct two types of scores to
135 cover the whole range of AUC: a score to predict whether an individual's AUC is in the top third
136 of the population (i.e., top AUC score, **Fig 2C**) and a score to predict whether an individual's AUC
137 is in the bottom third (i.e., bottom AUC score, **Supplementary Fig 2C**).

138 We first divided our dataset into training and test datasets. The training dataset consisted
139 of participants in Minami Soma City and Hirata Village (1775 individuals), and the test dataset
140 consisted of participants in Soma City (384 individuals). We used the training dataset for fitting
141 the scores. The algorithm searches the space of linear combinations of features with integer
142 coefficients from -5 to +5 to find the best combination to differentiate the population in the top third
143 of the training dataset from the rest (or the bottom third from the rest) (**Fig 2C**). We then assessed
144 the performance of these scores in the test dataset, that is, we tested whether the scores just
145 created could differentiate the population in the top third of the test dataset from the rest (or the
146 bottom third from the rest).

147 The top AUC scores in the test dataset were between -2 and 2, except for two individuals
148 with scores of -5 and 4, respectively (**Fig 2D** left). The 91 individuals with scores of 2 or more
149 (shown in yellow and orange) included 52 individuals (shown in yellow) whose AUC belonged to
150 the top third of the test dataset population (57.1%). The 104 individuals with a score of 1 included
151 46 individuals with AUC in the top third (44.2%). The 92 individuals with a score of 0 included 13
152 individuals with AUC in the top third (14.1%). The 78 individuals with a score of -1 included 16
153 individuals with AUC in the top third (20.5%). The 19 individuals with a score of -2 or less included
154 only 1 individual with AUC in the top third (5.2%). Thus, the higher an individual's top AUC score,

155 the more likely they were to belong to the top third of the population and have a higher AUC as
156 well (**Fig 2D** right). On the other hand, we calculated the bottom AUC scores in the test dataset,
157 which were between -4 and 2, except for one individual with a score of 3 (**Supplementary Fig**
158 **2D** left). We confirmed similar trends. For example, the 65 individuals with a score of 1 included
159 34 individuals with AUC in the bottom third (52.3%). Thus, the higher an individual's bottom AUC
160 score, the more likely they were to belong to the bottom third of the population and have a lower
161 AUC as well (**Supplementary Fig 2D** right). These results suggest that the personalized AUC
162 score can estimate individual antibody status with reasonable accuracy, helping individuals make
163 informed decisions about their disease prevention.

164 Discussion

165 In this study, we created a personalized antibody score that evaluates the antibody status
166 of individuals. To make an optimal score, we used a mathematical model of antibody production
167 in response to two-dose mRNA vaccinations, as developed in our previous paper (18), and
168 reconstructed the vaccine-elicited antibody dynamics of 2,159 participants from the Fukushima
169 vaccination cohort. Our mechanism-based mathematical modeling, in contrast to the statistical
170 modeling used in recent reports (3, 20), enabled biologically accurate description and precise
171 comparison of antibody dynamics. The parameters of the estimated dynamics showed a large
172 variation spanning two orders of magnitude. This variation was partially explained by individual
173 characteristics like age, sex, the interval between the two vaccine doses, adverse reactions,
174 comorbidities, and medications taken. This result is consistent with previous studies reporting age,
175 sex, vaccine interval, and comorbidities as factors affecting antibody titers (21, 22). Quantifying
176 the variability in antibody dynamics can be a basis for policy decisions regarding the distribution
177 of booster vaccines to strengthen immunity (23) or the use of oral antiviral drugs for the treatment
178 of breakthrough infections (24).

179 Our antibody scores can be easily calculated from individual demographic and health
180 information, yet have the ability to identify participants with high and low antibody titers (AUC of
181 the IgG(S) titers). Given the pleiotropic aspect of humoral immunity, it is surprising that a score
182 consisting of only 10 questionnaire items can give reasonable predictions. The score showed that
183 COVID-19 infection history and adverse reactions positively affect the AUC, whereas age,
184 diabetes, and collagen diseases negatively affect the AUC. These positive and negative factors
185 are consistent with previous studies (22, 25-28). In addition, diabetes and autoimmune diseases
186 have been reported to be risk factors for breakthrough infections (29, 30). Considering that
187 individual antibody titers are partially predictive of the likelihood of breakthrough infections (31,
188 32), this suggests that our antibody score could also be used as a risk score for breakthrough
189 infections. On the other hand, the antibody score also has some similarities with COVID-19
190 severity scores (33-37). In fact, both include age as a factor likely to lead to low antibody titers

191 and critical illness, both of which may be related to a defective immune system, as observable in
192 cytokine signatures (38, 39) or immunoglobulin responses (40, 41). However, whereas COVID-
193 19 severity scores use the results of laboratory tests and clinical symptoms to assess the patient's
194 condition in the hospital, our antibody score can be calculated on the basis of questionnaire
195 responses provided by individual (i.e., not limited to patients) themselves.

196 There are limitations to this study. The model fitting was based on limited antibody
197 measurements (two or three times for most participants) and the antibody score was solely based
198 on information available from the questionnaire. Further refinement of the score using additional
199 information will be a worthwhile task. It is worth mentioning that the immune system is affected
200 by multiple factors, including genetics, the environment (such as cohabitation), and markers of
201 metabolic health (42-45), all of which likely influence individual antibody status but were not
202 considered here. The biological determinants of antibody variation will be further revealed in future
203 studies addressing not only B cell subsets but the whole immune system encompassing adaptive
204 as well as innate immunity. At this stage, our score would best be used by medical practitioners
205 as a tool to advise individuals on getting booster vaccinations or taking additional precautions
206 against infection.

207 **Methods**

208 **Study data**

209 This study was conducted from April 2021 to December 2021 in Fukushima, Japan (called
210 the Fukushima vaccination cohort). A total of 2,526 participants who had been vaccinated with
211 Pfizer BNT162b2 or Moderna mRNA-1273 were recruited, and 2,159 participants were included
212 in the final data analysis. The participants included health care workers, frontline workers,
213 administrative officers, general residents, and residents of long-term care facilities. We here
214 investigated antibody titers of individuals sampled longitudinally (serum was collected at 2 or 3
215 different timepoints) for around 4 to 9 months after the second primary dose of mRNA vaccine.
216 Information on sex, age, daily medication, medical history, date of vaccination, adverse reactions
217 after vaccination, type of vaccination, blood type, Bacillus Calmette–Guérin (BCG) vaccine history,
218 smoking habits, and drinking habits were retrieved from the paper-based questionnaire
219 (summarized in **Supplementary Table 1**). In addition to the participants in the cohort, we included
220 12 health care workers whose serum had been sequentially sampled for 40 days (on average 25
221 samples per individual) in our analysis for the validation and parameterization of a mathematical
222 model for vaccine-elicited antibody dynamics. All serological assays were conducted at The
223 University of Tokyo. (S)-specific IgG (i.e., IgG(S)) and neutralizing activity were measured as the
224 humoral immune status after the COVID-19 vaccination. (N)-specific IgG antibody titers (IgG(N))
225 were used to determine past COVID-19 infection status (46). The study was approved by the
226 ethics committees of Hirata Central Hospital (number 2021-0611-1) and Fukushima Medical
227 University School of Medicine (number 2021-116). Written informed consent was obtained from
228 all participants individually before the survey. A portion of this cohort was described previously for
229 the period extending to 6 months after the first dose of mRNA vaccine (46, 47).

231 **Modeling vaccine-elicited antibody dynamics**

232 We recently developed a mathematical model describing COVID-19 vaccine-elicited
233 antibody dynamics to evaluate the impact of primary two-dose COVID-19 vaccination on rapid

234 immunity at the individual level and reconstructed the best-fit antibody titer curves of 2,407
235 participants in the Fukushima cohort (18). Here we explain the derivation and formulation of the
236 mathematical model in detail.

237

238 (i) Vaccination-elicited antibody dynamics after the first dose

239 After the first vaccination, naïve B cells encounter the antigens and differentiate into short-
240 lived antibody-secreting cells (ASCs), plasmablasts, germinal center (GC) B cells, or GC-
241 independent memory B cells depending on BCR affinity for their cognate antigen (48). Then, the
242 GC B cells undergo rapid proliferation with somatic immunoglobulin hypermutation and
243 subsequently differentiate into GC-dependent memory B cells or long-lived antibody-secreting
244 cells, which are plasma cells with immunoglobulin class switching. To describe this antigen-
245 specific B cell expansion and the induction of antibody-secreting cells and memory B cells after
246 the first vaccination (**Supplementary Fig 3A**), we developed a simple but quantitative
247 mathematical model as follows:

$$248 \quad \frac{dM_1(t)}{dt} = \begin{cases} 0 & (t < \tau_1) \\ -dM_1(t) & (t \geq \tau_1) \end{cases} \quad (1)$$

$$249 \quad \frac{dB(t)}{dt} = P_1(t) \frac{M_1(t)^m}{K^m + M_1(t)^m} - \mu B(t), \quad (2)$$

$$250 \quad \frac{dA(t)}{dt} = pB(t) - cA(t), \quad (3)$$

251 where the variables $M_1(t)$, $B(t)$, and $A(t)$ are the amount of mRNA inoculated by the
252 vaccination, the number of antibody-secreting cells, and the antibody titers at time t , respectively.
253 The parameters τ_1 and d represent the timing of the vaccination and the decay rate of mRNA.
254 We here considered D_1 to be the inoculated dose of mRNA by the vaccination, that is, $M_1(\tau_1) =$
255 D_1 .

256 Because the data we used here were limited (i.e., only time-course vaccine-elicited
257 IgG(S) titers), one compartment of B cells including heterogeneous cell populations that produce
258 antibodies (i.e., short-lived and long-lived antibody-secreting cells) was assumed. Therefore, we

259 modelled the average B cell population dynamics in Eq.(2), where the product of $P_1(t)$ and
 260 $M_1(t)^m/(M_1(t)^m + K^m)$ represents the average *de novo* induction of the antibody-secreting cells.
 261 $P_1(t)$ is a step function defined as $P_1(t) = P_1$ for $\tau_1 + \eta_1 \leq t$, where η_1 is the delay of induction
 262 of antibody-secreting cells after vaccination: otherwise $P_1(t) = 0$. The parameters m , K , and μ
 263 correspond to the steepness at which the induction increases with increasing amount of mRNA
 264 (i.e., the Hill coefficient), the amount of mRNA satisfying $P_1/2$, and the average decay rate of the
 265 antibody-secreting cell compartment, respectively. The other parameters, p and c , represent the
 266 antibody production rate and the clearance rate of antibodies, respectively.

267

268 (ii) Vaccination-elicited antibody dynamics after the second dose

269 After the second vaccination, the memory B cells are reactivated by re-exposure to the
 270 antigen. Some differentiate into short-lived antibody-secreting cells (plasmablasts) or memory B
 271 cells outside the GC. Others enter the GC to become secondary GC B cells. Subsequently, these
 272 secondary GC B cells differentiate into GC-dependent memory B cells or long-lived antibody-
 273 secreting cells (plasma cells). To describe these recall B cell responses and their secretion of
 274 antibody after the second vaccination (**Supplementary Fig 3B**), we modified the above
 275 mathematical model, Eqs.(1-3), as follows:

$$276 \quad \frac{dM_2(t)}{dt} = \begin{cases} 0 & (t < \tau_2) \\ -dM_2(t) & (t \geq \tau_2) \end{cases} \quad (4)$$

$$277 \quad \frac{dB(t)}{dt} = P_2(t) \frac{(M_1(t) + M_2(t))^m}{K^m + (M_1(t) + M_2(t))^m} - \mu B(t), \quad (5)$$

$$278 \quad \frac{dA(t)}{dt} = pB(t) - cA(t), \quad (6)$$

279 where $M_2(t)$ is the amount of mRNA by the vaccination inoculated at τ_2 satisfying $M_2(\tau_2) = D_2$.
 280 In addition, $P_2(t) = P_1$ for $\tau_2 \leq t < \tau_2 + \eta_2$, $P_2(t) = P_2$ for $\tau_2 + \eta_2 \leq t$, where η_2 is the delay of
 281 induction of antibody-secreting cells after vaccination; otherwise $P_2(t) = 0$. It should be noted
 282 that, prior to this main recall immunity, some rapid but small reactivation is observed, probably
 283 due to GC-independent memory B cells induced by the first vaccination (see participants S2, S7,

284 and S8 in **Supplementary Fig 1A**). This small reactivation is described by $P_1(M_1(t) + M_2(t))^m /$
285 $((M_1(t) + M_2(t))^m + K^m)$ for $\tau_2 \leq t < \tau_2 + \eta_2$. In general, once reactivated, memory B cells can
286 reenter the GC more rapidly than naïve B cells, and therefore the secondary antibody responses
287 are much faster and larger (i.e., $\eta_1 > \eta_2$ and $P_1 < P_2$, respectively). In the main recall immunity,
288 the quantity and quality of memory B cells established by the first vaccination is included in P_2 .

290 (iii) Mathematical model for data fitting

291 Since the clearance rate of antibody is much larger than the decay of antibody-secreting
292 cells (i.e., $c \gg \mu$), we made a quasi-steady state assumption, $dA(t)/dt = 0$, and replaced
293 Eqs.(3) and (6) with $A(t) = pB(t)/c$. Moreover, since Eqs.(1) and (4) are the linear differential
294 equations, $M_1(t) = D_1 e^{-dt}$ for $t \geq \tau_1$ and $M_2(t) = D_2 e^{-dt}$ for $t \geq \tau_2$: otherwise $M_1(t) =$
295 $M_2(t) = 0$, respectively. Thus, the above Eqs.(1-6) are further simplified assuming $\tau_1 = 0$ and
296 $D_1 > 0$, and we obtained the following single ordinary differential equation, which we used to
297 analyze the antibody responses (i.e., IgG(S) titers (AU/mL)) in this study:

$$298 \quad \frac{dA(t)}{dt} = H(t) \frac{(D_1 e^{-dt} + D_2 e^{-d(t-\tau_2)})^m}{K^m + (D_1 e^{-dt} + D_2 e^{-d(t-\tau_2)})^m} - \mu A(t), \quad (7)$$

299 where $H(t) = H_i = pP_i/c$ for $\tau_i + \eta_i \leq t < \tau_{i+1} + \eta_{i+1}$ ($i = 1$ or 2) and $D_2 > 0$ for $\tau_2 < t$:
300 otherwise $D_2 = 0$. This simple model can quantify the vaccine-elicited time-course antibody
301 dynamics as described in **Fig 1A** under an arbitrary threshold of antibody titers A_{TH} (see below).

302 303 Parameter estimations

304 To evaluate the primary two-dose COVID-19 vaccination leading to the antibody titers
305 (i.e., IgG(S) titers), we used a nonlinear mixed effects model to fit the antibody dynamics model,
306 given by Eq.(7), to the longitudinal antibody titers of IgG(S) obtained from the 12 health care
307 workers. Briefly, the parameters for individual k , $\theta_k (= \theta \times e^{\pi_k})$, are represented as a product of
308 θ (a fixed effect) and e^{π_k} (a random effect). π_k follows a normal distribution with mean 0 and
309 standard deviation Ω . We here assumed that the parameters H_1, H_2, η_1, η_2 , and m vary across

310 individuals, although we do not consider the inter-individual variability in other parameters to
311 ensure parameter identifiability. Note that the half-life of mRNA (i.e., $\log 2 / d$) and dose of mRNA
312 (i.e., D_i) are assumed to be 1 day (49) and 100 ($\mu\text{g}/0.5\text{mL}$) (50), respectively. We estimated
313 fixed effects and random effects using the stochastic approximation expectation-approximation
314 algorithm and empirical Bayes' method, respectively. Fitting was performed using MONOLIX
315 2019R2 (www.lixoft.com) (51). The estimated (fixed and individual) parameters are listed in
316 **Supplementary Table 2**.

317 With the estimated parameters for each individual, the dynamics of IgG(S) titers, $A(t)$,
318 and the average *de novo* antibody response elicited by the first and second vaccinations,
319 $H(t)(D_1e^{-dt} + D_2e^{-d(t-\tau_2)})^m / (K^m + (D_1e^{-dt} + D_2e^{-d(t-\tau_2)})^m)$, were calculated in
320 **Supplementary Fig 1A** and **1B**, respectively. Interestingly, we observed that the variations
321 induced by the second vaccination were much larger than those induced by the first vaccination
322 (**Supplementary Fig 1B**). Although we found that most of the best-fitted estimated parameters
323 in the mathematical model (i.e., μ , K , η_1 , η_2 , H_1) were the same or similar across the 12
324 individuals, the parameters m and H_2 , which contribute mainly to the vaccine-elicited antibody
325 dynamics after the second vaccination, showed wide variation of estimated values (see
326 **Supplementary Table 2**). Therefore, fixing these estimated population parameters except for m
327 and H_2 , we applied a nonlinear least squares method to reconstruct the large variations of the
328 antibody dynamics after the second dose for 2,159 participants. The best-fit antibody titer curves
329 are plotted along with the observed data for visualization in **Supplementary Fig 1C**, and the
330 distribution of parameter values m and H_2 are summarized in **Supplementary Fig 1D**.

331

332 **Random forest regressors for characterizing vaccine-elicited antibody dynamics**

333 Random forest regressors were trained to predict any of the three features of antibody
334 dynamics (log of peak, log of AUC, duration) on the basis of the participants' demographic and
335 health information as obtained by questionnaire (see Statistical analysis). randomForest and

336 rfPermute packages in R were used. The R squared values for each regressor were calculated
337 from OOB samples. Feature importance, which shows to what extent each factor was predictive
338 of the antibody dynamics features, was based on percentage increase in mean squared errors
339 and is shown as Chord diagrams (circlize package in R), in which arrows are drawn from each
340 feature to its predictive factors in a circular layout. Only the factors with $p < 0.05$ (obtained with
341 1,000 permutations) were selected and shown.

342

343 **Building optimized antibody scores**

344 A Python implementation of Ustun et al.'s (19) algorithm (risk-slim,
345 <https://github.com/ustunb/risk-slim>) was used to build optimized AUC scores. Briefly, the
346 algorithm searches for the best linear combination of features with integer coefficients that
347 minimizes the sum of the logistic loss and the l_0 -norm of the coefficients. The range of coefficients
348 was set to -5 to +5; the l_0 -penalty parameter C_0 was set to 5×10^{-4} .

349

350 **Statistical analysis**

351 Answers to the paper-based questionnaire collected from 2,159 participants were
352 converted into a set of categorical and numerical variables. Numerical variables included age and
353 the interval between the two doses. These variables were then used as input to predict the three
354 antibody dynamics features. Missing values of categorical variables were treated as a separate
355 category and were included in the analyses. The variables used here belonged to any of the five
356 categories: (i) basic demographic information and lifestyle habits, (ii) information on vaccinations,
357 (iii) underlying medical conditions, (iv) adverse reactions, and (v) medications being taken. When
358 necessary, the same variables were compared among different generations or different groups
359 using Pearson's chi-square test (for categorical variables), analysis of variance (ANOVA, for more
360 than two numerical variables), or Welch T-test (for two numerical variables). Pearson correlation
361 coefficient was calculated to evaluate the association between a pair of continuous variables. All
362 statistical analyses were performed using R (version 4.1.2).

363 **List of supplementary materials**

364 **Supplementary Figure 1** | Calibrating vaccine-elicited antibody dynamics

365 **Supplementary Figure 2** | Analyzing antibody titers

366 **Supplementary Figure 3** | Modeling vaccine-elicited B cell dynamics

367 **Supplementary Table 1** | Basic demographics

368 **Supplementary Table 2** | Estimated fixed and individual parameters

369

370 References

- 371 1. B. A. Dickerman *et al.*, Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in
372 U.S. Veterans. *N Engl J Med* **386**, 105-115 (2022).
- 373 2. J. Hippisley-Cox *et al.*, Risk prediction of covid-19 related death and hospital admission in adults
374 after covid-19 vaccination: national prospective cohort study. *BMJ* **374**, n2244 (2021).
- 375 3. J. Wei *et al.*, Antibody responses and correlates of protection in the general population after two
376 doses of the ChAdOx1 or BNT162b2 vaccines. *Nat Med* **28**, 1072-1082 (2022).
- 377 4. E. G. Levin *et al.*, Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6
378 Months. *N Engl J Med* **385**, e84 (2021).
- 379 5. C. Anastassopoulou *et al.*, Age and sex associations of SARS-CoV-2 antibody responses post
380 BNT162b2 vaccination in healthcare workers: A mixed effects model across two vaccination
381 periods. *PLoS One* **17**, e0266958 (2022).
- 382 6. J. Wei *et al.*, Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general
383 population of the United Kingdom. *Nat Microbiol* **6**, 1140-1149 (2021).
- 384 7. D. R. Feikin *et al.*, Duration of effectiveness of vaccines against SARS-CoV-2 infection and
385 COVID-19 disease: results of a systematic review and meta-regression. *Lancet* **399**, 924-944
386 (2022).
- 387 8. N. Doria-Rose *et al.*, Antibody Persistence through 6 Months after the Second Dose of mRNA-
388 1273 Vaccine for Covid-19. *N Engl J Med* **384**, 2259-2261 (2021).
- 389 9. J. Favresse *et al.*, Antibody titres decline 3-month post-vaccination with BNT162b2. *Emerg*
390 *Microbes Infect* **10**, 1495-1498 (2021).
- 391 10. M. Tre-Hardy, R. Cupaiolo, A. Wilmet, I. Beukinga, L. Blairon, Waning antibodies in SARS-
392 CoV-2 naive vaccinees: Results of a three-month interim analysis of ongoing immunogenicity and
393 efficacy surveillance of the mRNA-1273 vaccine in healthcare workers. *J Infect* **83**, 381-412
394 (2021).
- 395 11. A. V. Wisniewski, J. Campillo Luna, C. A. Redlich, Human IgG and IgA responses to COVID-19
396 mRNA vaccines. *PLoS One* **16**, e0249499 (2021).
- 397 12. A. Padoan *et al.*, Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and
398 comparison with SARS-CoV-2 immunoassays. *Clin Chem Lab Med* **60**, 456-463 (2022).
- 399 13. J. Van Praet *et al.*, Predictors and Dynamics of the Humoral and Cellular Immune Response to
400 SARS-CoV-2 mRNA Vaccines in Hemodialysis Patients: A Multicenter Observational Study. *J*
401 *Am Soc Nephrol* 10.1681/ASN.2021070908 (2021).
- 402 14. E. Terpos *et al.*, Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months
403 Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals.
404 *Hemasphere* **6**, e677 (2022).
- 405 15. D. Urlaub *et al.*, Neutralizing antibody responses 300 days after SARS-CoV-2 infection and
406 induction of high antibody titers after vaccination. *Eur J Immunol* **52**, 810-815 (2022).
- 407 16. F. J. Ibarondo *et al.*, Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody
408 Responses. *ACS Nano* 10.1021/acsnano.1c03972 (2021).
- 409 17. M. Meyer *et al.*, Humoral immune response after COVID-19 infection or BNT162b2 vaccine
410 among older adults: evolution over time and protective thresholds. *Geroscience* 10.1007/s11357-
411 022-00546-y (2022).
- 412 18. N. Nakamura *et al.*, Stratifying elicited antibody dynamics after two doses of SARS-CoV-2
413 vaccine in a community-based cohort in Fukushima, Japan. *medRxiv*
414 10.1101/2022.06.11.22276266, 2022.2006.2011.22276266 (2022).
- 415 19. B. Ustun, C. Rudin, Learning Optimized Risk Scores. *J Mach Learn Res* **20** (2019).
- 416 20. L. Perez-Alos *et al.*, Modeling of waning immunity after SARS-CoV-2 vaccination and
417 influencing factors. *Nat Commun* **13**, 1614 (2022).
- 418 21. H. Parry *et al.*, Extended interval BNT162b2 vaccination enhances peak antibody generation. *NPJ*
419 *Vaccines* **7**, 14 (2022).
- 420 22. H. Ward *et al.*, Population antibody responses following COVID-19 vaccination in 212,102
421 individuals. *Nat Commun* **13**, 907 (2022).

- 422 23. M. K. Patel, Booster Doses and Prioritizing Lives Saved. *N Engl J Med* **385**, 2476-2477 (2021).
423 24. R. Dal-Re, S. L. Becker, E. Bottieau, S. Holm, Availability of oral antivirals against SARS-CoV-2
424 infection and the requirement for an ethical prescribing approach. *Lancet Infect Dis*
425 10.1016/S1473-3099(22)00119-0 (2022).
426 25. N. N. M. Soetedjo, M. R. Iryaningrum, S. Lawrensia, H. Permana, Antibody response following
427 SARS-CoV-2 vaccination among patients with type 2 diabetes mellitus: A systematic review.
428 *Diabetes Metab Syndr* **16**, 102406 (2022).
429 26. R. Grainger, A. H. J. Kim, R. Conway, J. Yazdany, P. C. Robinson, COVID-19 in people with
430 rheumatic diseases: risks, outcomes, treatment considerations. *Nat Rev Rheumatol* **18**, 191-204
431 (2022).
432 27. N. Tani *et al.*, Relation of fever intensity and antipyretic use with specific antibody response after
433 two doses of the BNT162b2 mRNA vaccine. *Vaccine* **40**, 2062-2067 (2022).
434 28. A. Kanizsai *et al.*, Fever after Vaccination against SARS-CoV-2 with mRNA-Based Vaccine
435 Associated with Higher Antibody Levels during 6 Months Follow-Up. *Vaccines (Basel)* **10**
436 (2022).
437 29. S. Ahmed *et al.*, Postvaccination antibody titres predict protection against COVID-19 in patients
438 with autoimmune diseases: survival analysis in a prospective cohort. *Ann Rheum Dis* **81**, 868-874
439 (2022).
440 30. R. Marfella *et al.*, Glycaemic control is associated with SARS-CoV-2 breakthrough infections in
441 vaccinated patients with type 2 diabetes. *Nat Commun* **13**, 2318 (2022).
442 31. M. Z. Tay *et al.*, Decreased memory B cell frequencies in COVID-19 delta variant vaccine
443 breakthrough infection. *EMBO Mol Med* **14**, e15227 (2022).
444 32. M. Lipsitch, F. Krammer, G. Regev-Yochay, Y. Lustig, R. D. Balicer, SARS-CoV-2 breakthrough
445 infections in vaccinated individuals: measurement, causes and impact. *Nat Rev Immunol* **22**, 57-65
446 (2022).
447 33. S. Goodacre *et al.*, Derivation and validation of a clinical severity score for acutely ill adults with
448 suspected COVID-19: The PRIEST observational cohort study. *PLoS One* **16**, e0245840 (2021).
449 34. W. Liang *et al.*, Development and Validation of a Clinical Risk Score to Predict the Occurrence of
450 Critical Illness in Hospitalized Patients With COVID-19. *JAMA Intern Med* **180**, 1081-1089
451 (2020).
452 35. F. Gude *et al.*, Development and validation of a clinical score to estimate progression to severe or
453 critical state in COVID-19 pneumonia hospitalized patients. *Sci Rep* **10**, 19794 (2020).
454 36. C. Fumagalli *et al.*, Clinical risk score to predict in-hospital mortality in COVID-19 patients: a
455 retrospective cohort study. *BMJ Open* **10**, e040729 (2020).
456 37. I. Huespe *et al.*, COVID-19 Severity Index: A predictive score for hospitalized patients. *Med*
457 *Intensiva (Engl Ed)* 10.1016/j.medin.2020.12.001 (2020).
458 38. D. M. Del Valle *et al.*, An inflammatory cytokine signature predicts COVID-19 severity and
459 survival. *Nat Med* **26**, 1636-1643 (2020).
460 39. C. Lucas *et al.*, Longitudinal analyses reveal immunological misfiring in severe COVID-19.
461 *Nature* **584**, 463-469 (2020).
462 40. T. Zohar *et al.*, Compromised Humoral Functional Evolution Tracks with SARS-CoV-2
463 Mortality. *Cell* **183**, 1508-1519 e1512 (2020).
464 41. C. Lucas *et al.*, Delayed production of neutralizing antibodies correlates with fatal COVID-19.
465 *Nat Med* **27**, 1178-1186 (2021).
466 42. A. Liston, E. J. Carr, M. A. Linterman, Shaping Variation in the Human Immune System. *Trends*
467 *Immunol* **37**, 637-646 (2016).
468 43. T. Lakshminanth *et al.*, Human Immune System Variation during 1 Year. *Cell Rep* **32**, 107923
469 (2020).
470 44. P. Brodin *et al.*, Variation in the human immune system is largely driven by non-heritable
471 influences. *Cell* **160**, 37-47 (2015).
472 45. A. Liston, S. Humblet-Baron, D. Duffy, A. Goris, Human immune diversity: from evolution to
473 modernity. *Nat Immunol* **22**, 1479-1489 (2021).

- 474 46. Y. Kobashi *et al.*, The difference between IgM and IgG antibody prevalence in different
475 serological assays for COVID-19; lessons from the examination of healthcare workers. *Int*
476 *Immunopharmacol* **92**, 107360 (2021).
- 477 47. Y. Kobashi *et al.*, Seroprevalence of SARS-CoV-2 antibodies among hospital staff in rural Central
478 Fukushima, Japan: A historical cohort study. *Int Immunopharmacol* **98**, 107884 (2021).
- 479 48. B. J. Laidlaw, A. H. Ellebedy, The germinal centre B cell response to SARS-CoV-2. *Nat Rev*
480 *Immunol* **22**, 7-18 (2022).
- 481 49. P. Anand, V. P. Stahel, Correction to: The safety of Covid-19 mRNA vaccines: a review. *Patient*
482 *Saf Surg* **15**, 22 (2021).
- 483 50. D. Y. Lin *et al.*, Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina. *N*
484 *Engl J Med* **386**, 933-941 (2022).
- 485 51. P. Traynard, G. Ayral, M. Twarogowska, J. Chauvin, Efficient Pharmacokinetic Modeling
486 Workflow With the MonolixSuite: A Case Study of Remifentanyl. *CPT Pharmacometrics Syst*
487 *Pharmacol* **9**, 198-210 (2020).
- 488
489

490 Acknowledgments

491 We would like to thank all the staff from Fukushima Medical University, Seireikai health
492 care group, Hirata Village office, Soma City office, Soma Central Hospital, Soma General Hospital,
493 Minamisoma City office, Minamisoma City Medical Association, Minamisoma Municipal General
494 Hospital, Shindo Clinic and Medical Governance Institute, who contributed significantly to the
495 accomplishment of this research, especially, Ms. Yuka Harada, Ms. Serina Noji, Ms. Naomi Ito,
496 Dr. Makoto Kosaka, Mr. Anju Murayama, Mr. Sota Sugiura, Mr. Manato Tanaka, Ms. Yuna Uchi,
497 Mr. Yudai Kaneda, Mr. Masahiko Nihei, Mr. Hideo Sato, Ms. Rie Yanai, Ms. Yasuko Suzuki, Ms.
498 Keiko Abe, Dr. Hidekiyo Tachiya, Mr. Kouki Nakatsuka, Dr. Ryuzaburo Shineha, Ms. Miki Sato,
499 Dr. Masahiko Sato, Mr. Naoharu Tadano, Mr. Kazuo Momma, Mr. Shu-ichi Mori, Ms. Saori
500 Yoshisato, Ms. Katsuko Onoda, Mr. Satoshi Kowata, Mr. Masatsugu Tanaki, Dr. Tomoyoshi
501 Oikawa, Dr. Joji Shindo, Ms. Xujin Zhu, Ms. Asaka Saito, Ms. Yuumi Kondo, and Ms. Tomoyo
502 Nishimura. This study was supported by Medical & Biological Laboratories Co., Ltd., Shenzhen
503 YHLO Biotech Co., Ltd., the distributor and manufacturer of the antibody measurement system
504 (iFlash 3000), Research Center for Advanced Science and Technology in the University of Tokyo,
505 and in part by Scientific Research (KAKENHI) B 18H01139 (to S.I.), 16H04845 (to S.I.); Scientific
506 Research in Innovative Areas 20H05042 (to S.I.); AMED Strategic International Brain Science
507 Research Promotion Program 22wm0425011s0302 (to K.A.); AMED JP22dm0307009 (to K.A.);
508 AMED CREST 19gm1310002 (to S.I.); AMED Development of Vaccines for the Novel
509 Coronavirus Disease, 21nf0101638h0001 (to M.T.), 21nf0101638s0201 (to S.I.); AMED Japan
510 Program for Infectious Diseases Research and Infrastructure, 22wm0325007h0001 (to S.I.),
511 22wm0325004s0201 (to S.I.), 22wm0325012s0301 (to S.I.), 22wm0325015s0301 (to S.I.); AMED
512 Research Program on Emerging and Re-emerging Infectious Diseases 22fk0108140s0802 (to
513 S.I.); AMED Research Program on HIV/AIDS 22fk0410052s0401 (to S.I.); AMED Program for
514 Basic and Clinical Research on Hepatitis 22fk0210094 (to S.I.); AMED Program on the Innovative
515 Development and the Application of New Drugs for Hepatitis B 22fk0310504h0501 (to S.I.); AMED
516 Research Program on Hepatitis 19fk0210036h0502 (to S.I.), 19fk0310114h0103 (to S.I.); JST

517 MIRAI JPMJMI22G1 (to S.I.); Moonshot R&D JPMJMS2021 (to K.A. and S.I.) and JPMJMS2025
518 (to S.I.); The National Research Foundation of Korea (NRF) grant funded by the Korea
519 government (MSIT) (2022R1C1C2003637) (to K.S.K.); Shin-Nihon of Advanced Medical
520 Research (to S.I.); SECOM Science and Technology Foundation (to S.I.); The Japan Prize
521 Foundation (to S.I.); and Kowa Co (to M.T.).

522

523 **Author contributions**

524 SI designed the research. MT conducted the data collection. NN, HP, KSK, SIwanami,
525 KA, and SI carried out the computational analysis. SI supervised the project. All authors
526 contributed to writing the manuscript.

527

528 **Competing financial interests**

529 YKaneko is employed by Medical & Biological Laboratories, Co. (MBL, Tokyo, Japan).
530 MBL imported the testing material used in this research. YKaneko participated in the testing
531 process; however, he did not engage in the research design and analysis. YKobashi and MT
532 received a research grant from Pfizer Health Research Foundation for research not associated
533 with this work.

534

535 **Institutional review board statement**


536 This study was approved by the ethics committees of Hirata Central Hospital (number
537 2021-0611-1) and Fukushima Medical University (number 2021-116). This study was conducted
538 in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki).

539


540 **Informed consent statement**

541 Informed consent was obtained from all subjects involved in the study.

542




543 **Supplementary Figure 1 | Calibrating vaccine-elicited antibody dynamics: (A)** Observed and
 544 best-fitted IgG(S) titers are described for the 12 health care workers (HCWs) whose serum was
 545 sequentially sampled. The dashed vertical lines at day 21 correspond to the date of second
 546 vaccination. **(B)** Time-course averages of *de novo* antibody response elicited by the first and
 547 second vaccinations for the 12 HCWs are described. **(C)** Reconstructed individual antibody
 548 dynamics for the 2,159 participants are represented along with the measured IgG(S). The black
 549 circles correspond to the measurements of antibody titers at different time points. **(D)** Distributions
 550 of the estimated parameter values (i.e., H_2 and m) for 2,407 participants are plotted. Dataset for
 551 each distribution is normalized by the value corresponding to the 95th percentile of data values,
 552 and data whose values were larger than this value were removed to improve visibility of the figure.
 553



554

555 **Supplementary Figure 2 | Analyzing antibody titers: (A)** The distributions of two features of
 556 antibody dynamics (peak and AUC) in the cohort are shown. **(B)** Partial dependence plots
 557 showing the dependence of the two parameters (H_2 and m) on age or the interval are shown.
 558 **(C)** The bottom AUC score to identify individuals with AUC in the bottom third of the population is
 559 shown. **(D)** Left: The distribution of the bottom AUC score in the test dataset. 4, 69, 91, 83, 66,
 560 65, and 6 individuals had scores of -4, -3, -2, -1, 0, 1, or 2 or more, respectively. Those in the
 561 bottom third of the test dataset are shown in yellow, and those not in the bottom third are shown
 562 in orange. The ratio of individuals with AUC in the bottom third of the test dataset increased as
 563 the bottom AUC score increased. Right: the average AUC tended to decrease as the bottom AUC
 564 score increased.

565



Supplementary Figure 3 | Modeling vaccine-elicited B cell dynamics: (A) First vaccination-elicited antibody-secreting cell and memory B cell inductions are described. Once naïve B cells encounter vaccine antigens outside the germinal center (GC), the activated naïve B cells differentiate into short-lived antibody-secreting cells (ASCs), plasmablasts, GC B cells, or GC-independent memory B cells depending on BCR affinity for their cognate antigen. Subsequently, the GC B cells undergo rapid proliferation with somatic immunoglobulin hypermutation and differentiate into GC-dependent memory B cells or long-lived antibody-secreting cells (plasma cells), with immunoglobulin class switching. Through the GC-independent and dependent

574 pathways, antibody-secreting cells (i.e., $B(t)$) are induced and they secrete antibodies (i.e., $A(t)$).
575 **(B)** Second vaccination-elicited recall immune responses are described. After re-exposure to
576 vaccine antigens, memory B cells rapidly reactivate and expand. Of activated memory B cells,
577 while some differentiate into plasmablasts or memory B cells outside the GC, others enter the GC
578 to be secondary GC B cells. These secondary GC B cells differentiate into GC-dependent memory
579 B cells or plasma cells. In general, the secondary antibody responses are much faster and larger
580 by an order of magnitude compared with the first vaccination-elicited antibody responses.

Supplementary Table 1 | Basic demographics for the Fukushima vaccination cohort




Characteristic	<40 years	40-64 years	>65 years	Overall	p-value
Gender					0.001
Male	338(46.8)	421(38.2)	286(40.8)	1045(41.4)	
Vaccine type					0.015
BNT162b2 (Pfizer–BioNTech)	651(90.0)	971(88.1)	649(92.6)	2271(89.9)	
mRNA-1273 (Moderna)	0(0.0)	3(0.3)	0(0.0)	3(0.1)	
Days (mean [SD])					
from 1st dose	106.3[37.7]	104.4[35.1]	103.8[17.2]	104.8[32.0]	0.302
from 2nd dose	181.4[37.5]	180.1[35.7]	180.1[16.9]	180.5[32.2]	0.292
Blood type					
A	239(35.7)	427(39.0)	212(35.4)	878(37.2)	<0.001
B	151(22.6)	236(21.6)	140(23.4)	527(22.3)	<0.001
O	213(31.8)	326(29.8)	172(28.7)	711(30.1)	0.367
AB	66(9.9)	105(9.6)	75(12.5)	246(10.4)	0.432
BCG history	560(83.5)	907(83.1)	412(61.9)	1879(77.4)	0.395
Smoking	144(19.9)	253(23.0)	63(9.0)	460(18.2)	<0.001
Drinking Habit					<0.001
Almost not	403(55.7)	542(49.2)	458(65.3)	1403(55.5)	
Occasionally	247(34.2)	310(28.1)	90(12.8)	647(25.6)	
Everyday	63(8.7)	222(20.2)	127(18.1)	412(16.3)	
Daily Alcohol Consumption					<0.001
<20g	322(44.5)	382(34.7)	176(25.1)	880(34.8)	
20-40g	108(14.9)	214(19.4)	87(12.4)	409(16.2)	
40-60g	20(2.8)	60(5.4)	20(2.9)	100(4.0)	
>60g	5(0.7)	13(1.2)	2(0.3)	20(0.8)	
Comorbidities					
Hypertension	8(1.1)	237(21.5)	432(61.6)	677(26.8)	<0.001
Dyslipidemia	12(1.7)	123(11.2)	146(20.8)	281(11.1)	<0.001
Heart disease	14(1.9)	47(4.3)	140(20.0)	201(8.0)	<0.001
Diabetes	6(0.8)	72(6.5)	110(15.7)	188(7.4)	<0.001
Allergic disease	69(9.5)	95(8.6)	21(3.0)	185(7.3)	<0.001
Asthma	49(6.8)	45(4.1)	28(4.0)	122(4.8)	0.079
Liver disease	11(1.5)	45(4.1)	58(8.3)	114(4.5)	<0.001
Cancer	3(0.4)	35(3.2)	46(6.6)	84(3.3)	<0.001
Gout	5(0.7)	45(4.1)	26(3.7)	76(3.0)	0.001
Thyroid disease	8(1.1)	40(3.6)	11(1.6)	59(2.3)	0.005
Lung disease	12(1.7)	11(1.0)	28(4.0)	51(2.0)	<0.001
Mental disease	17(2.4)	16(1.5)	13(1.9)	46(1.8)	0.739
Rheumatism	2(0.3)	16(1.5)	19(2.7)	37(1.5)	0.006
Kidney disease	6(0.8)	7(0.6)	14(2.0)	27(1.1)	0.089
Anaphylaxis	6(0.8)	7(0.6)	5(0.7)	18(0.7)	0.994
Collagen disease	4(0.6)	6(0.5)	5(0.7)	15(0.6)	0.993
COVID-19 (family)	4(0.6)	5(0.5)	1(0.1)	10(0.4)	0.793
COVID-19	0(0.0)	3(0.3)	4(0.6)	7(0.3)	0.38
Immune deficiency	2(0.3)	4(0.4)	0(0.0)	6(0.2)	0.654
Others	51(7.1)	147(13.3)	189(27.0)	387(15.3)	<0.001
Drug					
Steroid	9(1.2)	23(2.1)	26(3.7)	58(2.3)	0.002
NSAIDs	31(4.3)	78(7.1)	82(11.7)	191(7.6)	<0.001
Acetaminophen	8(1.1)	22(2.0)	30(4.3)	60(2.4)	<0.001
Antihistamine	46(6.4)	65(5.9)	43(6.1)	154(6.1)	0.367
Immunosuppressants	6(0.8)	10(0.9)	8(1.1)	24(1.0)	0.432
Biologics	2(0.3)	5(0.5)	4(0.6)	11(0.4)	0.395
Anti-cancer agent	0(0.0)	5(0.5)	5(0.7)	10(0.4)	0.292



Adverse Reaction					
Local pain	515(71.2)	684(62.1)	228(32.5)	1427(56.5)	<0.001
Fatigue	511(70.7)	627(56.9)	119(17.0)	1257(49.8)	<0.001
Joint pain	327(45.2)	354(32.1)	90(2.8)	771(30.5)	<0.001
Fever (37.5 degrees or higher)	370(51.2)	308(28.0)	41(5.9)	719(28.5)	<0.001
Headache	321(44.4)	331(30.0)	34(4.9)	686(27.2)	<0.001
Fever (under 37.5 degrees)	137(19.0)	209(19.0)	40(5.7)	386(15.3)	<0.001
Dizziness	57(7.9)	45(4.1)	9(1.3)	111(4.4)	<0.001
Nausea	51(7.1)	41(3.7)	6(0.9)	98(3.9)	<0.001
Diarrhea	30(4.2)	25(2.3)	3(0.4)	58(2.3)	<0.001
Others	40(5.5)	69(6.3)	16(2.3)	125(5.0)	0.003

Values are No. (%) unless noted otherwise. BCG, bacille Calmette-Guérin; NSAID, nonsteroidal anti-inflammatory drug.

Supplementary Table 2. Estimated fixed and individual parameters for 12 health care workers


Parameter or variable	Decay rate of antibody-secreting cells	Maximum <i>de novo</i> production of antibody by 1 st vaccination	Delay of induction of antibody-secreting cells after 1 st vaccination	Steepness at which induction increases with increasing amount of mRNA	Amount of mRNA satisfying $P_i/2$	Maximum <i>de novo</i> production of antibody by 2 nd vaccination	Delay of induction of antibody-secreting cells after 2 nd vaccination
Symbol	μ	H_1	η_1	m	K	H_2	η_2
Unit	day ⁻¹	AU/mL	day	---	$\mu\text{g}/0.5\text{mL}$	AU/mL	day
Individual estimated parameters for S_1 to S_{12}							
S_1	0.885346	650.518	12.5269	0.0373144	33900	5227.34	4.21433
S_2	0.885346	760.114	12.5109	0.028673	33900	5035.79	4.23423
S_3	0.885346	2375.11	12.5096	0.0223842	33900	7562.82	3.85759
S_4	0.885346	790.745	12.4927	0.0611514	33900	7304.66	3.95306
S_5	0.885346	942.686	12.5169	0.0250174	33900	5638.12	3.91276
S_6	0.885346	448.87	12.5243	0.0851651	33900	3828.1	4.24752
S_7	0.885346	1848.01	12.5471	0.0272096	33900	9073.94	4.2513
S_8	0.885346	567.839	12.5409	0.0523284	33900	4673.2	4.71178
S_9	0.885346	1835.9	12.5428	0.0365247	33900	7517.48	4.59114
S_{10}	0.885346	1201.77	12.5109	0.0625655	33900	5916.28	4.17894
S_{11}	0.885346	736.229	12.5086	0.0700219	33900	4118.67	4.54006
S_{12}	0.885346	1369.65	12.5409	0.0488345	33900	8226.08	4.23969
Population estimated parameters							
---	0.885346	975.297	12.52	0.0437653	33900	6035.142	4.25





A**B****C**









C

1. COVID-19	5 points
2. Fever 37.5 or higher	1 point
3. Age under 40	1 point
4. Dyslipidemia	1 point
5. Age over 64	-1 points
6. Steroids	-1 points
7. Diabetes	-1 points
8. Liver disease	-1 points
9. Collagen disease	-5 points
10. Immune deficiency	-5 points
Add points from rows 1 to 10	Score





A**B****C**

1. Steroids	2 points
2. Age over 64	1 point
3. Immunosuppressants	1 point
4. Liver disease	1 point
5. Local pain	-1 points
6. Fever 37.5 or higher	-1 points
7. Age under 40	-1 points
8. Interval 28 or more	-1 points
9. Anaphylaxis	-1 points
10. COVID-19	-4 points
Add points from rows 1 to 10	Score

D